Hyaluronidase in the treatment of papular dermal mucinosis: First case reported in North America | Zendy

Arathi Ramamurthi | Zendy; Lindsay Bicknell | Zendy; Morgan McCarty | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hyaluronidase in the treatment of papular dermal mucinosis: First case reported in North America

Author(s) -

Arathi Ramamurthi,

Lindsay Bicknell,

Morgan McCarty

Publication year - 2016

Publication title -

journal of surgical dermatology

Language(s) - English

Resource type - Journals

eISSN - 2424-9165

pISSN - 2424-9084

DOI - 10.18282/jsd.v1.i2.43

Subject(s) - mucinosis , paraproteinemia , medicine , dermatology , paraproteinemias , myxedema , lupus erythematosus , mucin , systemic lupus erythematosus , pathology , monoclonal , disease , multiple myeloma , antibody , immunology , monoclonal antibody , thyroid

Papular mucinosis is an uncommon, idiopathic disorder characterized by dermal mucin deposition and increased collagen in the skin and internal organs. Its clinical presentation is characterized by dome-shaped, flesh colored papules that are closely spaced or linearly arranged. Papular mucinosis has been individually associated with several entities that include discoid lupus erythematosus, systemic lupus erythematosus and monoclonal gammopathy of undetermined significance. We encountered a 60-year-old woman with papular mucinosis in the setting of three concurrent disorders: discoid lupus erythematous, systemic lupus erythematosus and IgG paraproteinemia. Furthermore, we have reported the first case in North America of papular mucinosis being successfully treated with intralesional hyaluronidase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research